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Abstract
The implications of the methylene tetrahydrofolate reductase (MTHFR) gene and the level of homocysteine in the
pathogenesis of coronary artery disease (CAD) have been extensively studied in various ethnic groups. Our aim was
to discover the association of MTHFR (C677T) polymorphism and homocysteine level with CAD in north Indian sub-
jects. The study group consisted of 329 angiographically proven CAD patients, and 331 age and sex matched
healthy individuals as controls. MTHFR (C677T) gene polymorphism was detected based on the polymerase chain
reaction and restriction digestion with HinfI. Total homocysteine plasma concentration was measured using
immunoassay. T allele frequency was found to be significantly higher in patients than in the control group. We found
significantly elevated levels of mean homocysteine in the patient group when compared to the control group (p =
0.00). Traditional risk factors such as diabetes, hypertension, smoking habits, a positive family history and lipid pro-
files (triglyceride, total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol), were found significantly
associated through univariate analysis. Furthermore, multivariable logistics regression analysis revealed that CAD is
significantly and variably associated with diabetes, hypertension, smoking, triglycerides and HDL-cholesterol. Our
findings showed that MTHFR C677T polymorphism and homocysteine levels were associated with coronary artery
disease in the selected population.
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Introduction
Coronary artery disease (CAD) is the consequence of
atherosclerotic plaque disposition on the coronary artery
wall. Its manifestation depends on interactions between en-
vironmental and genetic risk factors (Andreassi et al.,
2003). Individual susceptibility to the disease has been as-
sociatedwithfunctionalallelicvariation.Thus,theidentifi-
cation of gene polymorphisms relating to the formation of
atherosclerotic plaques, and consequently, thrombi, may
contribute towards developing early diagnostic methods
and guiding preventive procedures (Arruda et al., 1998;
Doevendans et al., 2001; Andreassi et al., 2003). The gene
that encodes methylene tetrahydrofolatereductase enzyme
(MTHFR), which is involved in the metabolism of homo-
cysteine (Hcy), is of great interest in clinical practice (Rob-
inson et al., 1995; Hofmann et al., 2001; Andreassi et al.,
2003).Hcy,anaminoacidderivedfromproteincatabolism,
is present in the plasma in several forms, with the greatest
proportion (70%) bound to albumin (Doevendans et al.,
2001). High levels of Hcy (hyperhomocysteinemia) have
been identified as a risk factor for atherosclerosis (Bova et
al., 1999; Hankey and Eikelboom, 1999; Lobo et al., 1999;
Doevendans et al., 2001; Andreassi et al., 2003). The
mechanism for the vascular lesions induced by
hyperhomocysteinemiaremainsunclear.Experimentalevi-
dence suggests that Hcy facilitates the vascular oxidative
process, thereby altering the coagulation system, and re-
duces the vasomotor regulation of the endothelium (Welch
et al., 1997; Tyagi, 1998; Hankey and Eikelboom, 1999;
Hofmann et al., 2001). The aim of this study was to assess
the relationship between MTHFR gene polymorphism and
plasma homocysteine level with the traditional risk factors
of coronary artery disease in a north Indian population.
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Research ArticleMaterial and Methods
Study subjects
Patients, with evidence of more than 50% stenosis in
coronary arteries, a past history of prior angioplasty, or
CAD by-pass grafting, were included in the present study.
The patients were recruited from the outpatient and inpa-
tient services of the Department of Cardiology, SGPGIMS
during the period February, 2006 to November, 2008. The
study group included angiographically proven CAD pa-
tients. The control group consisted of individuals without a
CAD background and with negative results in treadmill-
stress tests. The two groups were age and sex matched. An
individual clinical background entailing the presence of di-
abetes, hypertension, smoking habits, CAD family history,
body-mass index and complete lipid profile (serum triglyc-
erides, total cholesterol, HDL, LDL and VLDL) were fur-
nished by members of both the patient and control groups
independently. Diabetes and hypertension was diagnosed
in patients and controls, based on prior medical records or
standard clinical examination and tests, according to the
standard definition described by Fauci et al. (2008). Habit-
ual smoking was defined as prevailing at least one year be-
fore CAD onset. A family history of CAD was defined
based on its presence in first-degree relatives. Body-mass
index was calculated by dividing the weight in kilograms
by the square of the height in meters (Fouci et al., 2008).
Patients and controls included in the study were natives of
Uttar Pradesh. Exclusion criteria were cardiomyopathy, a
febrile condition, rheumatic heart disease, congenital heart
disease and systemic disorders. A prior written informed
consent was obtained from patients and controls. The study
was approved by an institutional ethics committee.
DNA preparation and genotyping
Genomic DNA was extracted from EDTA peripheral
blood leukocytes by the standard phenol-chloroform
method (Poncz et al., 1982). The quality of DNA was
checked through 0.8% agarose (Sigma, USA) gel electro-
phoresis, and quantification was done on a UV spectropho-
tometer (Specgene Ltd, UK). Synthetic oligonucleotides
were acquired from Genetix, France. Primers (Forward
5’TGA AGG AGA AGG TGT CTG CGG GA3’, Reverse
5’AGG ACG GTG CGG TGA GAG TG3’) for exon 4 of
the MTHFR gene were used as described by Frost et al.
(1995). Amplification was done in an automated thermo-
cycler (BioRad PTC100, USA). The mixture was initially
denatured at 94 °C for 4 min, followed by 30 cycles with
30 s at 94 °C, 45 s at 62 °C, 45 s at 72 °C and a 12 min final
extension at 72 °C. PCR products were checked on 2% of
agarosegelsfollowedbystainingwith1g/mLofethidium
bromide. . The amplified PCR products of 198 bp were di-
gested with HinfI (NEB UK) restriction enzyme according
to manufacturer’s specifications. The restriction digestion
productswereseparatedona3%agarosegelandvisualized
by ethidium bromide staining (Figure 1).
Biochemical analyses
Fastingvenousbloodfrompatientsandcontrolswere
collectedinplainvialsinordertoanalyzetriglyceride(TG)
levels. These levels were measured by lipoprotein lipase-
peroxidase (Fossati and Prencipe, 1982), those of total cho-
lesterol (TC) by cholesterol oxidase (Allain et al., 1974)
and those of high density lipoprotein (HDL) by phospho-
tungstatemagnesiumchloridemethodology(Lopes-Virella
etal.,1977).Verylowdensitylipoprotein(VLDL)andlow
density lipoprotein (LDL) levels were calculated indirectly
by means of the Friedwald formula (Friedewald et al.,
1972) as (VLDL-C = TG/5 provided TG = 400 mg/dL) and
LDL-C = TC – (HDL-C + VLDL-C). Total plasma homo-
cysteine levels were determined in 87 patients and 79 con-
trols by enzyme linked immunoassay (Microplate EIA Ho-
mocysteine BioRad, USA). The assay method was based
on enzymatic conversion of homocysteine to S-adenosyl
homocysteine, followed by quantification of S-adenosyl-
L-homocysteine by an enzyme- linked immunoassay
(Frantzen et al., 1998).
Statistical analysis
Genotype and allele frequencies in CAD and control
groups were compared by Chi square testing. The charac-
teristicsofpatientsandcontrolswereevaluatedbycompar-
ing biochemical findings using the Student t-test.
Additionally, we performed multiple logistic regression
model testing on the interaction of genotype and different
classicalCADriskfactors.Allanalyseswereperformedus-
ing SPSS v.11.5 (SPSS Inc., Chicago, USA) statistical
analysissoftware.Atwo-tailedpvalueofp<0.05wascon-
sidered statistically significant.
Results
The study group included 329 angiographically
proven CAD patients [80 with myocardial infarction (MI),
and the remaining 249 with no past reference], and 331 in-
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Figure1-DetectionofMTHFRpolymorphism.Lanes2,3,5and6show-
ing wild type (CC) genotype, lane 1 showing mutant heterozygous (CT)
genotype and lane 4 showing mutant homozygous (TT) genotype, M
showing molecular weight Marker.dividuals as controls with no clinical history of CAD. The
clinical and demographic data of patients and controls are
presented in Table 1. Classical risk factors, viz., diabetes,
hypertension, smoking and family history were signifi-
cantly higher in the CAD group than in the control. The
value of HDL- cholesterol was significantly lower in CAD
patients than in controls, although serum triglyceride, total
cholesterol, LDL-cholesterol, VLDL-cholesterol and
homocysteine levels were found to be significantly higher
in the former.
Allele and genotype frequencies in both patient and
control group are described in Table 2. The distribution of
genotypes within each group was in Hardy-Weinberg equi-
librium. We found the prevalence of the CT genotype to be
11.5% in the control and 18.2% in the patient group,
whereas almost similar mutant homozygous frequencies
(1.5%and2.8%)wereobservedincontrolsandpatients,re-
spectively. T allele frequency was significantly higher in
the patient group (11.9%) than the control (7.3%)
(p = 0.004, OR 1.75 95% CI 1.16-2.55). On compiling a
subgroup of MI and non-MI patients, we found that 63 out
of 80 MI patients (78.6%) presented a CC genotype, 13
(16.25%) a CT genotype, and 4 (5.0%) were homozygous
for the T allele (TT genotype). C and T allele frequencies
were 87% [139] and 13% [21], respectively, in the MI pa-
tient group. This indicates a significant association of the T
allele with myocardial infarction in patients in contrast to
control [p = 0.016 (Fisher exact), OR 1.93 (95% CI
1.08-3.44)].
When we assessed the severity of the disease in terms
of the number of vessels involved in CAD and MTHFR
polymorphism, interestingly we found no variation in T al-
lele prevalence in either one, two or three vessels [12.7%,
10.0% and 11.0%, respectively] with stenosis in a CAD pa-
tient. Similarly findings were observed with homocysteine
levels (Table 3). Significantly high levels of homocysteine
were observed in the patient group as compared to the con-
trol, irrespective of the genotypes involved (CC, CT and
TT) (Table 3).
On performing multiple logistic regression analysis;
to see the influence of various risk factors on CAD precipi-
tation (Table 4), we found that, in the case of diabetes, hy-
pertension, smoking, triglyceride and HDL-cholesterol,
this was significantly variable for CAD. We additionally
observed that an increase to 10 mg/dL in Triglyceride, To-
tal cholesterol and LDL-cholesterol, will increase the risk
of CAD by 1.3 times, 1.01 times and 1.08 times, respec-
tively, whereas a 10 mg/dL decrease in HDL-cholesterol
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Table 1 - Characteristics of controls and patients.
Characteristics Controls CAD Patients p-value
N 331 329 -
Age 53.18  9.18* 57.09  9.66* 0.217
Sex (M:F) 245:86 260:69 0.142
BMI 25.12  3.12* 25.54  2.97* 0.077
Diabetic: nondiabetic 82:249 142:187 0.000
Hypertensive: nonhypertensive 76:255 156:173 0.000
Smoker: nonsmoker 33:299 66:263 0.000
Positive family history: negative family history 04:329 13:316 0.028**
Triglyceride (45-150 mg/dL) 95.75  27.95* 165.04  81.33* 0.000
Total Cholesterol (125-250 mg/dL) 154.70  39.73* 170.29  48.56* 0.000
HDL-cholesterol (23-60 mg/dL) 38.34  7.79* 36.51  7.01* 0.002
LDL-cholesterol (92-148 mg/dL) 97.82  31.72* 103.99  43.67* 0.039
VLDL-cholesterol (10-30 mg/dL) 19.59  6.65* 29.80  13.90* 0.000
Homocysteine (5-15 M/L) 11.11  4.39 16.05  8.51 0.000
*Mean  SD, ** p-value (Yates correction).
Table 2 - Distribution of genotype and allele frequencies in patients and controls.
Genotype/Allele Control (N = 331) Patient (N = 329) OR p-value 95% CI
CC 288 (87.0%) 260 (79.0%)
CT 38 (11.5%) 60 (18.20%) 0.054
TT 5 (1.5%) 9 (2.8%)
C allele 614 (92.7%) 580 (88.1%) 1.75 0.004 1.16-2.55
T allele 48 (7.3%) 72 (11.9%)leads to a 2.5 times greater risk of CAD. This indicates that
HDL-C is more crucial for CAD. Furthermore a concurrent
increase in MTHFR CT and TT genotypes leads to an even
greater CAD risk (1.3 times and 1.2 times, respectively)
than CC genotype.
Discussion
The implication of the MTHFR gene in CAD patho-
genesis has been extensively studied in several ethnic
groups. We found a significantly higher frequency of T al-
lelesinCADpatientsthanincontrols.ORinthisgroupwas
1.75. Other epidemiological studies that estimated the risk
of CAD associated with the T allele showed conflicting re-
sults. Notwithstanding, Kerkeni et al. (2006) and Alam et
al.(2008)foundthissubstitutiontobeasignificantriskfac-
tor. On summarizing the results from 8 studies, Kluijtmans
et al. (1996) encountered no significant difference for the T
allele, although they reported higher frequencies (31.8%
and 29% in patient and control group respectively).
We found the T allele to be significantly associated
with myocardial infarction (p = 0.016, OR1.93, 95% CI
1.08-3.44).Thisfindingisconsistentwithapreviousreport
(Gülec et al., 2001) in which MTHFR C677T transition
wasfoundtobeariskfactorforprematureMI.Ontheother
hand, other authors ( Anderson et al., 1997; Hsu et al.,
2001) reported insignificant differences for the T allele be-
tween MI subjects and the control group. We observed al-
most equal frequencies for the CC, CT and TT genotypes,
irrespective of one-, two- or three-vessel-stenosis, Our
findings are in accordance with previous reports (Van
Bockxmeeretal.,1997;Kerkenietal.,2006;Rassouletal.,
2008), in which insignificant association was observed.
Nevertheless, for Morita et al. (1997) the association was
significant. Furthermore, we noted that the severity of the
disease is independent of homocysteine levels. Likewise,
Wang et al. (1999) found no correlation between the level
of homocysteine and severity of the disease, whereas Ras-
soul et al. (2008), on the contrary, discovered a positive as-
sociation.
In our study, the average homocysteine level was sig-
nificantly higher in the patient group than in the control.
This is in agreement with observations by other investiga-
tors (Evans et al., 1997; Kerkeni et al., 2006). The finding
of a significant correlation between 5,10 methylene tetra-
hydrofolate reductase enzyme activity and MTHFR geno-
types (Frosst et al., 1995) (70% reduced activity in the TT
genotypeand35%reducedactivityintheCTgenotype)im-
plieselevatedhomocysteinelevelsinthesetwogenotypes.
A previous study by Alam et al. (2008) on 100 coro-
nary artery cases and 100 controls, also from North India,
demonstrated the positive association of MTHFR (C677T)
gene polymorphism. The present study is in agreement, al-
though with a larger-sized sample, and undertaken with
certain restrictions, such as using a single MTHFR genetic
marker (C677T). Thus, further polymorphic MTHFR
markers need to be evaluated, together with the other ge-
netic markers involved in the Homocysteine pathway for
predisposition to the disease.
Coronary artery disease is a complex disorder where
environmental and genetic markers both play an important
role.
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